http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
RFID 사용요인이 신뢰, 지각된 위험, 모바일RFID환경 하에서 사용의도에 미치는 영향 -약국RFID 시스템을 중심으로-
최재영 ( Jae Young Choi1 ),차재빈 ( Jae Bin Cha1 ),김상만 ( Sang Man Kim ) 경희대학교 경영연구원 2013 의료경영학연구 Vol.7 No.1
This study examined the influence of various factors of RFID use in mobile RFID environment, focusing on pharmacies` RFID systems. The purpose of the study was to verify the possibility of a more widespread use of RFID and mobile RFID in medical industry by exploring what impact RIFD use factors have on the intention to use in RFID environment. The subjects were pharmacists who have their own pharmacies in Seoul and Gyeonggi Province. Of 400 questionnaires distributed to the respondents, 392 were used in the final analysis except 8 with insufficient answers. The empirical analysis results showed that perceived security, perceived cost, and social influence had significant impacts on trust, while social influence and perceived cost had significant impacts on perceived risk. Among RFID use factors, social influence, perceived security, and perceived risk had significant impacts on intention to use in mobile RFID environment. Trust and perceived cost did not have a significant impact. The summary of analysis results, implications, and limitations are presented in the conclusion.
( Sang Hyeok Im ),( Dong Hwan Kim ),( Young Hoon La ),( Nam Jin Kim ),( Cha Won Hwang ),( Jae Min Cha ),( Bong Ki Ryu ) 대한금속재료학회 ( 구 대한금속학회 ) 2010 재료마당 Vol.23 No.3
This study looks at crystallization and sintering behavior in B2O3 containing Li2O-Al2O3-SiO2 glass powder. The sintered sample was produced with glass powders measuring 44 μm. The relative density and transmittance of the sintered samples showed the highest value at the temperature of 650°C. At temperatures higher than 650°C, crystal growth occurred to decrease the densification of B2O3-Li2O-Al2O3-SiO2 (BLAS) glass powder. The main crystalline phase in the glass powder was a-spodumene. From non-isothermal differential thermal analysis, the crystallization of particles (Φ=44 μm) was observed at 640°C to 684°C with respect to the heating rate. The activation energy of crystallization (E(C)) and the Avrami constant (n) calculated by Kissinger and Ozawa equations indicated that the surface and the bulk crystallization occurred simultaneously in the glass. The optimum sintering temperature of this glass powder was 650°C without crystal growth of β-spodumene, although nucleation or nano-crystal growth occurred.
Renal Precursor Cell Transplantation Using Biodegradable Polymer Scaffolds
( Sang Soo Kim ),( Heung Jae Park ),( Joung Ho Han ),( Min Sun Park ),( Moon Hyang Park ),( Kang Won Song ),( Kwan Joong Joo ),( Cha Yong Choi ),( Byung Soo Kim ) 한국미생물생명공학회 2005 Journal of microbiology and biotechnology Vol.15 No.1
Jae Young Cha(차재영),Sang Min Shin(신상민),Se Eun Ha(하세은),Jung Sup Lee(이정섭),Jong Kun Park(박종군) 한국생명과학회 2011 생명과학회지 Vol.21 No.12
세포주기조절에서 유전자 발현의 조절은 매우 중요한 부분이다. 본 연구에서는 인간의 유전자인 CIP29/Hcc1과 상동성을 가지는 분열형 효모의 새로운 유전자 mas1+을 분리하였다. 중합효소연쇄반응을 수행하여 cDNA를 얻고 이 cDNA의 염기서열을 분석한 결과 mas1+의 전체 염기서열은 735 bp로서, 245개의 아미노산을 암호화하고 있다. mas1+의 프로모터에서는 M-G1에 특이적인 전사를 보이는 유전자들에 보존되어 있는 PCB 서열이 발견되었다. 세포주기별 mas1+의 전사 수준을 분석한 결과 격막이 형성된 세포수의 빈도를 나타내는 격막 세포지표의 양상과 유사하게 발현하는 것을 확인하였다. mas1+ 결손 돌연변이를 25℃와 36℃에서 배양한 결과, 세포질 분열과정이 늦어진 다중격막 세포의 빈도가 증가하였다. 이를 FACS로 분석하여 DNA 함량이 2C, 4C와 6C등이 형성됨을 확인하였다. mas1+결손 돌연변이 세포를 질소 결핍 배양액에서 배양한 결과 다중격막 세포의 형성이 확연히 증가하였는데 이는 질소 결핍에 따른 세포분열의 가속화 단계에서 mas1+의 결손이 특히 부정적 영향을 초래함을 시사한다. mas1+ 유전자 결손 돌연변이 세포에 mas1+을 포함한 plasmid를 형질전환한 후 mas1+의 발현을 유도한 결과 정상의 세포 형태로 전환됨을 확인하였다. Mas1 단백질에 EGFP를 융합시켜 발현을 유도한 결과 핵내에서 위치함을 분열형 효모와 인간 배양세포인 HeLa에서 확인하였다. 또한, mas1+ 결손 돌연변이에서 상동성을 가지는 인간 유전자 CIP29/Hcc1을 발현시킨 결과 multi-septate 세포가 줄어들었다. 한편, 생쥐의 배발달 단계에 따른 CIP29 유전자의 전사체 수준은 세포 분열이 활발한 시기에 증가하였다. 이상의 결과들은 Mas1은 인간의 핵단백질인 유전자 CIP29/Hcc1과 구조 기능적으로 상동성을 가지며, 세포주기 중 M-G1에 속하는 세포질 분열에 연관되어 있음을 시사한다. The regulation of gene expression plays an important role in cell cycle controls. In this study, a novel gene, the mas1?(mitosis associated protein) gene, a homolog of human CIP29/Hcc1, was isolated and characterized from fission yeast Schizosaccharomyces pombe (S. pombe) using a gene-specific polymerase chain reaction. The isolated gene contained a complete open reading frame capable of encoding 245 amino acid residues with a typical promoter, as judged by nucleotide sequence analysis. It was also found that a PCB (pombe cell cycle box) is located in the promoter region, which controls M-G1 specific transcription in S. pombe. The quantitative analysis of the mas1? transcript against adh1? showed that the pattern of expression is similar to that of the septation index. Cytokinesis of mas1 null mutant was greatly delayed at 25℃ and 36℃, and a large number of multi-septate cells were produced. The mas1 null mutant had 2C, 4C and 6C DNA contents, as determined by FACS analysis. In addition, the number of multi-septate cells significantly increased. When cells were cultured in nitrogen starvation medium to increase proliferation, the abnormal phenotypes of mas1 null mutant dramatically increased. These phenotypes could be rescued by an overexpression of the mas1+ gene. The mas1 protein localized in the nuclei of S. pombe and human HeLa cells, as evidenced by Mas1-EGFP signals. The abnormal growth pattern and the morphology of mas1 null mutant were complemented by a plasmid carrying human CIP29/Hcc-1cDNA. In addition, CIP29 /Hcc-1 transcript level increased in active cell proliferation stages in the developing mouse embryos. These results indicate that the mas1? ishomologous to the human CIP29/Hcc1 gene and is involved in cytokinesis and cell shape control.
HCV, Alcoholic : O-023 ; Novel inhibitory effect of ginsenoside Rg3 in HCV replication and apoptosis
( Jae Young Jang ),( Eun Kyung Cho ),( Soung Won Jeong ),( Jin Woo Choo ),( Jin Nyoung Kim ),( Soon Ha Kwon ),( Sae Hwan Lee ),( Sang Gyune Kim ),( Sang Woo Cha ),( Young Seok Kim ),( Young Deok Cho ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background/Aim: Pegylated Interferon and ribavirin are standard therapy of chronic hepatitis C. There is an increasing need to identify more optimal strategies for treating this disease, especially viable treatment options for patients who are intolerable to interferon. We investigated the anti-HCV (Hepatitis C Virus) effect of ginsenoside using a HCV cell culture model. Methods: We used ginsenosides (Ro, Re, Rg1, Rg2, Rg3, Rh1, Rh2) with different concentrations (10, 25, 50, 100μM) for the treatment of JFH-1 (HCV) infected Huh 7.5.1 cells. MTT assay was performed for cytotoxicity of ginsenoside. JFH-1 mRNA, HCV core and cleaved PARP antibody were used for HCV replication and apoptosis, respectively. We compared HCV replication and apoptosis between ginsenoside-treated and interferon-treated JFH-1 infected Huh 7.5.1 cells. Activation of transcriptional factor was evaluated by NFκB. Results: 1) Cytotoxicity was minimal in ginsenoside-treated JFH-1 infected Huh 7.5.1 cells except 100 μM of Rh2. 2) Prominent decreased JFH-1 mRNA level and HCV core were found in Rg3 treated JFH-1 infected Huh 7.5.1 cells compared to other ginsenoside treated JFH-1 infected Huh 7.5.1 cells by Real-time PCR and western blot, respectively. 3) Marked decreased cleaved PARP was shown in Rg3 treated JFH-1 infected Huh 7.5.1 cells compared to other ginsenoside treated JFH-1 infected Huh 7.5.1 cells. 4) The degree of anti-HCV and anti-apoptosis after treating Rg3 was dose dependent manner. 5) The anti-viral and anti-apoptotic effect of Rg3 was very similar with interferon treated JFH-1 infected Huh 7.5.1 cells in a dose dependent manner. 6) Phosphorylation of NFκB was increased in Rg3 treated JFH-1 infected Huh 7.5.1 cells compared to other cell lines (p<0.001). Conclusion: Ginsenoside Rg3 has a marked anti-HCV effect without cell toxicity in JFH-1 infected Huh 7.5.1 cells in a dose dependent manner and this effect is mediated by induction of NFκB (Korean Patent Application No.:10-2012-0001800).
Cha, Ran-hui,Kang, Shin Wook,Park, Cheol Whee,Cha, Dae Ryong,Na, Ki Young,Kim, Sung Gyun,Yoon, Sun Ae,Han, Sang Youb,Chang, Jae Hyun,Park, Sue K.,Lim, Chun Soo,Kim, Yon Su American Society of Nephrology 2016 CLINICAL JOURNAL- AMERICAN SOCIETY OF NEPHROLOGY Vol.11 No.4
<P>Background and objectives The notion that oral intestinal sorbent AST-120 slows renal disease progression has not been evaluated thoroughly. In this study, we investigated the long-term effect of AST-120 on renal disease progression (doubling of serum creatinine, eGFR decrease >50%, or initiation of RRT) in patients with advanced CKD. Design, setting, participants, & measurements We prospectively recruited 579 patients (CKD stage 3 or 4) from 11 medical centers in Korea from March 4, 2009 to August 31, 2010 and randomized them into an AST-120 arm and a control arm. Patients in the AST-120 arm were given 6 g AST-120 in three divided doses per day, and those in the control arm received only standard conventional treatment (open-label design) for 36 months or until the occurrence of primary outcomes. Results Levels of serum and urine indoxyl sulfate and beta 2-microglobulin decreased throughout the study period in both treatment arms; however, there was not a significant difference in change in uremic toxins in the AST-120 and control arms. The two arms were not different in the occurrence of composite primary outcomes (100 events in 272 individuals in the AST-120 arm and 100 events in 266 individuals in the control arm; hazard ratio, 1.12; 95% confidence interval, 0.85 to 1.48; log-rank P=0.45). The decline in eGFR and change in proteinuria were similar in the two treatment arms over time (Prandomization-time=0.64 and Prandomization-time=0.16, respectively). There was no difference in mortality (nine deaths in the AST-120 arm and 11 deaths in the control arm; log-rank P=0.73) or unplanned hospitalizations (102 in the AST-120 arm and 109 in the control arm; log-rank P=0.76) in the two treatment arms. There was no significant difference of the health-related quality of life score between the two arms. Conclusions Long-term use of AST-120 added to standard treatment did not change renal disease progression, proteinuria, mortality, and health-related quality of life in patients with advanced renal dysfunction.</P>
Genetic Distribution of Carbapenem-Resistant Enterobacteriaceae in Seoul Korea, 2018~2020
Sang-Hun Park,So-Hyun Park,Jin-Seok Kim,Jin-Kyung Yu,Jin-Kyoung Kim,Hyo-Sun Suh,Eun Young Kwon,Kyoung Ae Park,Eui Kyung Cha,Jae Min Shin,Hyo-Won Jeoung,Su-Jin Jeon,Young-Ok Hwang,Jib-Ho Lee,Yong-Seoun 대한바이러스학회 2022 Journal of Bacteriology and Virology Vol.52 No.1
( Sang-Cheol Bae ),( Jin-Hye Cha ),( Jung-Yoon Choe ),( Sung Jae Choi ),( Soo-Kyung Cho ),( Won-Tae Chung ),( Chung-Il Joung ),( Young-Ok Jung ),( Young Mo Kang ),( Dong-Wook Kim ),( Jinseok Kim ),( Y 대한류마티스학회 2018 대한류마티스학회지 Vol.25 No.2
Objective. Productivity loss was compared by 3-stage of disease activity and associations between higher disease activity and high productivity loss were identified. Methods. Data were extracted from Rheumatoid Arthritis (RA) Patient-reported Outcomes Research, which enrolled 2,000 RA patients (>20-year) on disease-modifying-antirheumatic-drugs (DMARDs) (≥ 6-month) from December 2012 to June 2013. This included 1,457 RA patients with the disease activity score (DAS-28-ESR) in their medical charts. Productivity loss in time and indirect cost was estimated using The World Health Organization Health and Work Performance Questionnaire (HPQ). Baseline characteristics and productivity loss outcomes were compared according to DAS-28-ESR groups. Results. 84.4% were females, 54.2% had low DAS-28-ESR (<3.2), and 38.2% and 7.6% had moderate (3.2∼5.1) and high DAS-28-ESR (>5.1). Patients with moderate to high DAS-28-ESR had higher lost productivity time (LPT) and monthly costs of LPT than those with low DAS-28-ESR (time in hours: 110.0±58.4 vs. 132.4±57.2 vs. 71.5±52.0, p<0.0001; monthly costs of LPT in 1,000 Korean won: 1,097±607 vs. 1,302±554 vs. 741±531, p<0.0001). Multiple regression analyses revealed significant associations with high LPT in high (adjusted odds ratio [OR]=3.87, 95% confidence interval [CI]: 2.18∼6.87) and moderate DAS-28-ESR (adjusted OR=1.88, 95% CI: 1.41∼2.52) compared to low DAS-28-ESR. In addition, positive associations with high monthly costs of LPT were observed in high (adjusted OR=3.45, 95% CI: 1.98∼5.99) and moderate DAS-28-ESR (adjusted OR=1.93, 95% CI: 1.43∼2.54) compared to low DAS-28-ESR. Conclusion. Timely therapeutic strategies should be taken into consideration given that the RA patients with moderate to high DAS-28-ESR showed strong associations with high productivity loss for effective management of RA. (J Rheum Dis 2018;25:122-130)